This Phase II trial is enrolling 60 participants with acute spinal cord injury to test the effect of a nerve-supporting stem cell product injected into the spinal fluid. The cells (XS228) are derived from lab-grown nerve cells that support and repair nerves. If included, participants will be randomly assigned to receive either XS228 cells or a placebo, delivered via 4 spinal fluid injections over 6 weeks, alongside standard rehabilitation. Final testing for arm and leg function, sensation, bladder/bowel function, and safety will be performed after 1 year.
Type
Details
- Participants will be randomly assigned to receive either XS228 or a placebo, delivered via 4 spinal fluid injections over 6 weeks, alongside standard rehabilitation. - XS228 is a treatment made from lab-grown nerve cells that support and repair nerves. - Final testing will be performed after 1 year.
Main benefits
General health
Additional benefits
Arm/hand function
Bladder health/function
Bowel health
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more